Description
Waylivra (volanesorsen) is an injectable medication used to treat familial chylomicronemia syndrome (FCS). FCS is a rare genetic disorder that causes high levels of triglycerides in the blood, leading to inflammation of the pancreas and an increased risk of pancreatitis.
Uses:
Waylivra is used to reduce the frequency of pancreatitis episodes in patients with FCS. It is intended for use in patients with severe or multiple pancreatitis episodes who have not responded to standard therapy.
Storage Conditions:
Waylivra should be stored in the refrigerator at 36°F to 46°F (2°C to 8°C). The medication should not be frozen or shaken.
Mechanism of Action:
Waylivra works by decreasing the production of apolipoprotein C-III (apoC-III), a protein that regulates the clearance of triglycerides from the blood. In patients with FCS, the excess apoC-III leads to increased levels of triglycerides, which can cause pancreatitis. Waylivra helps to reduce the amount of apoC-III in the blood, which lowers triglyceride levels and reduces the risk of pancreatitis.
HOW TO USE:
Waylivra is administered by subcutaneous injection once a week. The dose is based on the patient’s weight and should be determined by the healthcare provider. Patients should be trained on how to administer the injection or have a caregiver who is trained to do so.
Precautions:
• Waylivra should not be used in patients with active liver disease.
• Patients should be monitored for signs of liver dysfunction, including abdominal pain, nausea, vomiting, fatigue, or jaundice.
• Patients who develop liver dysfunction should discontinue Waylivra immediately and receive appropriate medical care.
• Waylivra should be used with caution in patients taking anticoagulant medications, as it may increase the risk of bleeding.
Drug Interactions:
• Waylivra may interact with anticoagulant medications, increasing the risk of bleeding. Patients taking anticoagulants should be monitored closely while taking Waylivra.
Contraindications:
• Waylivra should not be used in patients with active liver disease.
• Waylivra is contraindicated in patients with a history of hypersensitivity to volanesorsen.
Overdose:
There is limited information on the effects of overdose with Waylivra. In case of overdose, patients should seek immediate medical attention.
Adverse Reactions:
The most common adverse reactions to Waylivra include injection site reactions, such as redness, swelling, or pain, gastrointestinal symptoms, such as nausea and diarrhea, and flu-like symptoms, such as fever and headache. Patients should notify their healthcare provider if they experience any unusual symptoms while taking Waylivra.
In summary, Waylivra is an injectable medication used to treat familial chylomicronemia syndrome (FCS), a genetic disorder that causes high levels of triglycerides in the blood, leading to inflammation of the pancreas and an increased risk of pancreatitis. It works by decreasing the production of apolipoprotein C-III (apoC-III), a protein that regulates the clearance of triglycerides from the blood. Waylivra is administered by subcutaneous injection once a week and dosed based on the patient’s weight. It should be stored in the refrigerator and not be frozen or shaken. Patients with active liver disease or hypersensitivity to volanesorsen should not use Waylivra. Adverse reactions include injection site reactions, gastrointestinal symptoms, and flu-like symptoms. Waylivra should be used with caution in patients taking anticoagulant medications.
Reviews
There are no reviews yet.